2025
Potential roles for vitamin D in preventing and treating impulse control disorders, behavioral addictions, and substance use disorders: A scoping review
Jalilian-Khave L, Kitaneh R, Ysrayl B, Borelli A, Funaro M, Potenza M, Angarita G. Potential roles for vitamin D in preventing and treating impulse control disorders, behavioral addictions, and substance use disorders: A scoping review. Addiction Neuroscience 2025, 14: 100190. DOI: 10.1016/j.addicn.2024.100190.Peer-Reviewed Original ResearchImpulse control disordersSubstance use disordersControl disordersBehavioral addictionsTreating impulse control disordersVitamin DClinical studiesAddictive disordersSerotonergic circuitsExposure to vitamin DVitamin D deficiencyVitamin D levelsSymptom presenceDisordersPotential beneficial effectsJoanna Briggs InstituteD deficiencyPotential therapeutic mechanismAddictionD levelsWeb of ScienceTherapeutic mechanismQuality of studiesCochrane LibraryOvid MEDLINE
2024
A review of the kappa opioid receptor system in opioid use
Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, DOI: 10.1016/j.neubiorev.2024.105713.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsKappa opioid receptor systemKappa-opioid receptorsOUD subjectsKappa-opioid receptor expressionOpioid withdrawal symptomsWithdrawal symptomsDynorphin levelsPeripheral blood lymphocytesOpioid useDrug-seeking/taking behaviorAnti-reward systemsKappa-opioid receptor antagonistClinical studiesCerebrospinal fluidOpioid receptor systemKOR/dynorphin systemDisorder subjectsOpioid receptorsOpioid intoxicationBlood lymphocytesReceptor systemOpioidWeb of ScienceClinical roleDynorphin
2022
Current status of clinical outcome measures in inclusion body myositis: a systematised review.
Roy B, Lucchini M, Lilleker J, Goyal N, Naddaf E, Adler B, Alfano L, Malandraki G, Focht Garand K, Mochel D, Badrising U, Machado P, Pagkatipunan R, Ramdharry G, Wang L, Funaro M, Schmidt J, Kushlaf H, Schiopu E, Stipancic K, Goyal N, d'Alessandro M, Conticini E, Cruz-Coble B, Lloyd T. Current status of clinical outcome measures in inclusion body myositis: a systematised review. Clinical And Experimental Rheumatology 2022, 41: 370-378. PMID: 36762744, DOI: 10.55563/clinexprheumatol/ifacv3.Peer-Reviewed Original ResearchConceptsIBM functional rating scaleInclusion body myositisIdiopathic inflammatory myopathiesOutcome measuresClinical studiesBody myositisMuscle testingClinical trialsMaximal voluntary isometric contraction testingOpen-label clinical trialSix-minute walk distanceSporadic inclusion body myositisQuantitative muscle testingSecondary outcome measuresManual muscle testingPrimary outcome measureClinical outcome measuresCore set measuresNew potential therapeuticsSuitable outcome measuresThigh muscle volumeDifferent outcome measuresInflammatory myopathiesWalk distancePharmacological therapy